Primiano Christopher Brett 4
4 · Karyopharm Therapeutics Inc. · Filed Sep 10, 2020
Insider Transaction Report
Form 4
Primiano Christopher Brett
VP, Gen Counsel & Secretary
Transactions
- Sale
Common Stock
2020-09-08$14.98/sh−10,054$150,609→ 4,649 total - Exercise/Conversion
Common Stock
2020-09-08$6.54/sh+10,054$65,753→ 14,703 total - Exercise/Conversion
Stock Option (right to buy)
2020-09-08−10,054→ 0 totalExercise: $6.54Exp: 2026-01-14→ Common Stock (10,054 underlying)
Footnotes (2)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 15, 2017, and the remaining 75% vested in 36 equal monthly installments thereafter.